Citation
- Authors: Boot, A., Oosting, J., de Miranda, N. F., Zhang, Y., Corver, W. E., van de Water, B., Morreau, H., van Wezel, T.
- Year: 2016
- Journal: J Pathol
- Applications: in vitro / siRNA / INTERFERin
- Cell type: TT2609-C02
Description: human follicular thyroid carcinoma cell line
Method
Cells were seeded at 5 000 cells/well in 96-well plates. 24 h later, cells were transfected using 50 nM siRNA with 0,3 % of INTERFERin. Medium was changed 24 h later. siRNA knockdown was analysed 48 h-post transfection.
Abstract
The genomes of a wide range of cancers, including colon, breast and thyroid cancers frequently show copy number gains of chromosome 7 and rarely show loss of heterozygosity. The molecular basis for this phenomenon is unknown. Strikingly, oncocytic follicular thyroid carcinomas can display an extreme genomic profile, with homozygosity of all chromosomes except for chromosome 7. The observation that homozygosity of chromosome 7 is never observed suggests that retention of heterozygosity is essential for cells. We hypothesized that cell survival genes are genetically imprinted on either of two copies of chromosome 7 which thwarts loss of heterozygosity at this chromosome in cancer cells. By employing a DNA methylation screen and gene expression analysis we identified six imprinted genes that force retention of heterozygosity on chromosome 7. Subsequent knockdown of gene expression showed that CALCR, COPG2, GRB10, KLF14, MEST and PEG10 were essential for cancer cell survival resulting in reduced cell proliferation, G1 -phase arrest and increased apoptosis. We propose that imprinted cell survival genes provide a genetic basis for retention of chromosome 7 heterozygosity in cancer cells. The monoallelically expressed cell survival genes identified in this study, and the cellular pathways they are involved in, offer new therapeutic targets for the treatment of tumours showing retention of heterozygosity on chromosome 7. DNA methylation data has been submitted to GEO under accession number GSE77804.